Comparative Pharmacology
Head-to-head clinical analysis: JAIMIESS versus LESSINA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JAIMIESS versus LESSINA 28.
JAIMIESS vs LESSINA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norepinephrine and dopamine reuptake inhibitor; also weakly inhibits serotonin reuptake. Enhances synaptic concentrations of norepinephrine and dopamine, particularly in prefrontal cortex.
Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.
100 mg orally once daily with food.
One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in severe impairment).
Terminal elimination half-life: 18-22 hours; clinically relevant for once-daily dosing.
Primarily renal excretion as unchanged drug (approximately 70%) with the remainder as inactive metabolites; less than 10% excreted in feces.
Renal: 30% as unchanged drug and metabolites; biliary/fecal: 70% as metabolites.
Category C
Category C
Oral Contraceptive, Combined
Oral Contraceptive